Effects of altitude (4300 M) on the pharmacokinetics of caffeine and cardio-green in humans

Abstract

The effects of chronic exposure to high altitude on the pharmacokinetics of caffeine and cardiogreen (ICG) were examined in eight healthy males (23–35 y) at sea level (SEA) and following 16 days residence at 4300 m (ALT). ICG (0.5 mg · kg⁻¹) was administered as an intravenous bolus and caffeine (4 mg · kg⁻¹) in an orally ingested solution. The concentration of ICG, caffeine, and the primary metabolites of caffeine (MET) were determined in serial blood samples and their pharmacokinetics computed. In comparison to SEA, ALT resulted in a significant decrease in the caffeine half-life (t_1/2, 4.7 vs 6.7 h) and area under the curve (2.5 vs 3.7 g · 1⁻¹ · min⁻¹), and increased clearance (117 vs 86 ml · min⁻¹ · 70 kg⁻¹). In ALT the area under the curve of ICG significantly decreased (85 vs 207 mg · 1⁻¹ · min⁻¹) and the volume of distribution and clearance increased (5.2 vs 2.41 and 532 vs 234 ml · min⁻¹ respectively) compared to SEA. There was a significant increase in the AUC ratio of MET to caffeine indicating that either metabolite formation or elimination was increased in ALT. These results demonstrate that in humans, chronic exposure to 4300 m results in the modification of the pharmacokinetics of caffeine and ICG.